Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Restricted
Select Page
EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

by Communication Team | Jan 21, 2021 | ODYSSEY, Publication

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close...

Recent Posts

  • ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
  • New European-African Project that will develop UNIVERSAL treatments for children living with HIV
  • EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir
  • Cheaper HIV treatment for children: a report in the Lancet
  • European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV

Recent Comments

    Archives

    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is Penta Foundation